invIOs GmbH
VIENNA, October 15, 2024 (Globe Newswire) — invIOs GmbH (“invIOs”), a privately held biotechnology company developing new treatments for cancer, today announced that the company has raised €8.2 million in Series A funding. announced that it had procured. Participation of existing shareholders and Ligand Pharmaceuticals. Ligand recently acquired APEIRON, the former parent company of invIOs. This funding will ensure continued pipeline progress and achievement of clinical and preclinical milestones through 2025.
Peter Llewellyn-Davies, CEO and CFO of invIOs, said: We are especially grateful for the strong support of our existing shareholders and the commitment of our new shareholder, Ligand Pharmaceuticals. ”
invIOs also provided an update on recent advances in two major anti-cancer programs, INV441 and INV501. The company collaborates with Dana-Farber Cancer Institute (DFCI) on both programs in the field of glioblastoma. The collaboration is led by David Reardon, MD, clinical director of the DFCI Neuro-Oncology Center and professor at Harvard Medical School. Dr. Reardon is a world-renowned expert in the research and treatment of brain tumors, particularly glioblastoma.
“We are excited about the progress of our collaboration with DFCI on both our oral small molecule candidate, INV501, and our current cell therapy candidate, INV441. is developing cancer treatments that have the potential to address major unmet needs in the treatment of deadly tumors, and is committed to continuing its research to ultimately improve and save patient lives. We are excited,” said Dr. Romana Gugenberger. , chief medical science officer at invIOs.
INV501 is a first-in-class orally available small molecule. In July 2024, invIOs announced the selection of lead candidates from the compound family. Preclinical studies have shown convincing efficacy and safety results for this candidate in both breast cancer and melanoma models, as well as the ability to cross the blood-brain barrier and mount an anti-tumor immune response. has been.
the story continues
IND-enabling toxicology studies are underway and preparations for manufacturing under GMP conditions are underway. Target validation efforts are expected to be completed and mechanism of action details will be provided in the first quarter of 2025.
INV441 cell therapy. INV441 uses tumor-infiltrating lymphocytes (TILs) modified with siRNA that inhibits the immune checkpoint Cbl-b and administered directly to the tumor. This approach demonstrated strong preclinical proof of concept in a murine glioma model. In 2024, invIO submitted significant IP for this program. invIOs recently held a pre-IND meeting with the US Food and Drug Administration (FDA). At the meeting, FDA provided valuable information for a planned Phase 1 trial with INV441 that will be conducted by DFCI and is expected to begin in mid-2025.
Meet invIO’s management at the LSX Inv€$tival Showcase™ in London on November 18th
Peter Llewellyn-Davies, CEO and CFO, and Dr. Romana Gugenberger, Chief Medical and Scientific Officer, will deliver the company presentation and host the 1X1 meeting at this important industry event. To schedule a conference, please use our conference partner system or contact us at Invests@invios.com.
About invIO
invIOs is a privately held biotechnology company based in Vienna, Austria, focused on discovering and developing new treatments for cancer. The invIOs team leverages deep expertise in immune system activation to develop personalized and targeted approaches to solid tumors. invIOs is advancing a pipeline of programs that include small molecule and cell therapy approaches.
INV501 is a novel small molecule candidate that can selectively enhance T cell-mediated antitumor immune responses. INV501 is currently in preclinical testing and has demonstrated preclinical proof of concept with strong data in multiple solid tumor indications following oral administration. A lead candidate compound for clinical development has been selected and IND-enabling research is underway.
invIOs’ proprietary cell therapy platform, EPiC, enables rapid outpatient treatment. EPiC is a technology platform that enables the creation of personalized cell therapies based on local processing of a patient’s fresh immune cells. Proof of concept was demonstrated by early clinical results for APN401, the first asset of the EPiC platform. INV441, also derived from EPiC, is being developed for the treatment of glioblastoma and is in preclinical trials. invIOs is collaborating with DFCI on this program. Another EPiC program, INV451, is a new CAR-T cell approach for lung cancer that is being developed in collaboration with the Medical University of Innsbruck.
For more information, please visit www.invios.com and connect with us on LinkedIn.
contact address
invIO
Peter Llewelyn Davies
CEO/CFO
Phone +43 1 8656577 0
Email: Investors@invios.com
MC Service AG
Dr. Cora Kaiser, Dr. Regina Lutz
Phone +49 89 210 228 0
America: Laurie Doyle
Phone +1-339-832-0752
Email: invios@mc-services.eu
